THE SURVIVAL OF CRYOPRESERVED HUMAN BONE MARROW STEM CELLSHILL RS; MACKINDER CA; POSTLEWAIGHT BF et al.1979; PATHOLOGY; AUS; DA. 1979; VOL. 11; NO 3; PP. 361-367; BIBL. 12 REF.Article

A TECHNIQUE FOR THE CONCENTRATION OF NUCLEATED BONE MARROW CELLS FOR IN VITRO MANIPULATION OR CRYOPRESERVATION USING THE IBM 2991 BLOOD CELL PROCESSORGILMORE MJML; PRENTICE HG; CORRINGHAM RE et al.1983; VOX SANGUINIS; ISSN 0042-9007; CHE; DA. 1983; VOL. 45; NO 4; PP. 294-302; BIBL. 27 REF.Article

USE OF MODIFIED SUBCUTANEOUS RIGHT-ATRIAL CATHETER FOR VENOUS ACCESS IN LEUKAEMIC PATIENTSBLACKLOCK HA; HILL RS; CLARKE AG et al.1980; LANCET; GBR; DA. 1980; VOL. 8176; PP. 993-994; BIBL. 6 REF.Article

SEROLOGICAL COMPLICATIONS OF A MAJOR ABO INCOMPATIBLE BONE MARROW TRANSPLANTATION IN A POLYNESIAN WITH APLASTIC ANEMIAOCKELFORD PA; HILL RS; NELSON L et al.1982; TRANSFUSION (PHILA.); ISSN 0041-1132; USA; DA. 1982; VOL. 22; NO 1; PP. 62-65; BIBL. 13 REF.Article

USE OF ANTI-T-CELL MONOCLONAL ANTIBODY OKT3 TO PREVENT ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR ACUTE LEUKAEMIAPRENTICE HG; BLACKLOCK HA; JANOSSY G et al.1982; LANCET (BR. ED.); ISSN 0140-6736; GBR; DA. 1982; NO 8274; PP. 700-703; BIBL. 33 REF.Article

ABO-INCOMPATIBLE BONE-MARROW TRANSPLANTATION: REMOVAL OF RED BLOOD CELLS FROM DONOR MARROW AVOIDING RECIPIENT ANTIBODY DEPLETIONBLACKLOCK HA; GILMORE MJML; PRENTICE HG et al.1982; LANCET (BR. ED.); ISSN 0140-6736; GBR; DA. 1982; NO 8307; PP. 1061-1064; BIBL. 21 REF.Article

ABSCENCE OF CLOSE LINKAGE BETWEEN HEREDITARY SPHEROCYTOSIS (SPH) AND 24 GENETIC MARKER SYSTEMS INCLUDING HLA AND GMDEJONGH BM; BLACKLOCK HA; REEKERS P et al.1983; ANNALS OF HUMAN GENETICS; ISSN 0003-4800; GBR; DA. 1983; VOL. 47; NO 1; PP. 55-65; BIBL. 2 P.Article

KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTSHANN IM; PRENTICE HG; CORRINGHAM R et al.1982; LANCET (BR. ED.); ISSN 0140-6736; GBR; DA. 1982; NO 8276; PP. 826-829; BIBL. 26 REF.Article